2 June 2016 - Following a request for proposals for the supply of influenza vaccine, issued on 3 February 2016, PHARMAC is seeking feedback on a provisional agreement with BGP Products Pty. Ltd (trading as Mylan EPD) to list an influenza vaccine in the Pharmaceutical Schedule for the 2017, 2018 & 2019 influenza seasons.

In summary, this proposal would result in:

• Influvac being listed in Section H and Section I of the Pharmaceutical Schedule from 1 January 2017 under the eligibility criteria set by PHARMAC.
• Community sole supply status being awarded to Mylan EPD, for its brand(s) of influenza vaccine.
• A change from the trivalent vaccine (Influvac) to the quadrivalent vaccine (Influvac Tetra) from the first full influenza season following market approval by Medsafe for Influvac Tetra.

For more details, go to: http://www.pharmac.govt.nz/news/consultation-2016-06-02-influenza-vaccine/